4 research outputs found
Clinical Significance of Age at the Time of Diagnosis among Young Breast Cancer Patients
PURPOSE: The aims of this study were to investigate outcomes corresponding to age at diagnosis as categorized into 5-year intervals and to explore whether endocrine-responsive tumors display clinical benefits from endocrine therapy after chemotherapy among young breast cancer patients.
METHODS: A total of 1,171 patients who were under 40 years old at diagnosis between 1985 and 2007 were divided into 3 subgroups: â¤30 years (Group I, 13.3%), 31-35 years (Group II, 30.5%), and 36-40 years (Control group, 56.2%). Clinicopathological factors and outcomes were compared using a chi-square test, the Kaplan-Meier method, and Cox's hazards models.
RESULTS: There were no significant differences in the characteristics and treatment patterns between the 3 groups, except for the grade, hormone receptors expression, and use of endocrine therap. Group I showed the worst survival and subsequently Group II presented worse outcomes than the Control group, mainly among hormone receptors-positive patients. Groups I and II showed increased risks of recurrence and death in multivariate analyses. Among 529 hormone receptors-positive patients who received chemotherapy, favorable outcomes for patients who were treated with endocrine agents were demonstrated, mainly in patients aged 35 years or less. However, interaction tests between the use of endocrine therapy and age at diagnosis were not significant.
CONCLUSION: Age at diagnosis is an independent prognostic factor and the age of 35 years is a rational cut-off among young patients. Our subgroup analysis suggests that endocrine therapy may provide additional benefits even in young breast cancers. Therefore, further researches should be directed towards improving outcomes for this population.ope
The 70-Gene Prognostic Signature for Korean Breast Cancer Patients
Purpose: A 70-gene prognostic signature has prognostic value in patients with node-negative breast cancer in Europe. This diagnostic test known as âMammaPrint TM (70-gene prognostic signature)â was recently validated and implementation was feasible. Therefore, we assessed the 70-gene prognostic signature in Korean patients with breast cancer. We compared the risk predicted by the 70-gene prognostic signature with commonly used clinicopathological guidelines among Korean patients with breast cancer. We also analyzed the 70-gene prognostic signature and clinicopathological feature of the patients in comparison with a previous validation study. Methods: Forty-eight eligible patients with breast cancer (clinical T1-2N0M0) were selected from four hospitals in Korea. Fresh tumor samples were analyzed with a customized microarray for the 70-gene prognostic signature. Concordance between the risk predicted by the 70-gene prognosti
Search for Physics Beyond the Standard Model in Opposite-Sign Dilepton Events at âs=7 TeV
A search is presented for physics beyond the standard model (SM) in final states with opposite-sign isolated lepton pairs accompanied by hadronic jets and missing transverse energy. The search is performed using LHC data recorded with the CMS detector, corresponding to an integrated luminosity of 34 pb. -1. No evidence for an event yield beyond SM expectations is found. An upper limit on the non-SM contribution to the signal region is deduced from the results. This limit is interpreted in the context of the constrained minimal supersymmetric model. Additional information is provided to allow testing the exclusion of specific models of physics beyond the SM.0CMS Collaborationinfo:eu-repo/semantics/publishe